A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease



Status:Terminated
Conditions:Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:18 - Any
Updated:1/5/2019
Start Date:November 14, 2014
End Date:February 27, 2017

Use our guide to learn which trials are right for you!

A Phase 2A Study of ALXN1007 in Subjects With Newly Diagnosed Acute Graft-Versus-Host Disease Involving the Lower Gastrointestinal Tract

The objectives of this trial were to evaluate the safety, tolerability,
pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of intravenous (IV) ALXN1007 in
participants with acute graft-versus-host disease (GVHD) of the lower gastrointestinal (GI)
tract.

This was a Phase 2A open-label, non-randomized study to evaluate the safety, tolerability,
PK/PD, and efficacy of ALXN1007 (a C5a inhibitor) in up to 36 participants with newly
diagnosed acute GVHD of the lower GI tract. All participants meeting the inclusion and
exclusion criteria for the study were to receive ALXN1007 over an 8 week treatment period.
Participants in Cohort 1, the first dosing cohort, were to receive 10 milligrams/kilogram
(mg/kg) ALXN1007 administered IV once weekly for 8 weeks. Participants in Cohort 2 were to
receive 20 mg/kg ALXN1007 IV once weekly for 8 weeks. Participants in Cohort 3 were to
receive 20 mg/kg ALXN1007 IV twice weekly for 8 weeks. All doses of ALXN1007 were to be
administered as a continuous IV infusion.

Inclusion Criteria:

- Participants must be males or females age 18 years or older.

- Participants with Stage 1 to 4 (per the Modified Keystone Grading Schema) acute GVHD
of the lower GI tract, without signs of chronic GVHD, at the time of diagnosis, which
developed in the first 180 days following allogeneic hematopoietic cell
transplantation (HCT) using bone marrow, peripheral blood, or cord blood; or after
preplanned donor lymphocyte infusion.

- Participants are willing to undergo or must have had an endoscopy of the upper and/or
lower GI tract and biopsy to confirm GI GVHD.

- Participants must be receiving systemic corticosteroids.

- Participants with an absolute neutrophil count (ANC) >500/microliter (μL) at
Screening.

- Participants and spouse/partner who are of childbearing potential must be using high
effective contraception consisting of 2 forms of birth control (at least 1 of which
much be barrier method) starting at Screening and continuing through the entire study
(for at least 3 months after the last dose of ALXN1007 if study treatment is stopped
early or participant withdraws consent).

- Male participants must not donate sperm during the Screening and Treatment periods,
and for at least 3 months after the last dose of ALXN1007.

- Stage of acute GVHD of the lower GI tract will be determined using the Modified
Keystone Grading Schema.

Exclusion Criteria:

- Participants with a body weight > 140 kg (for Cohorts dosing 20 mg/kg of ALXN1007 and
higher only).

- Participants with signs and symptoms of chronic GVHD.

- Participants with an active uncontrolled infection.

- Participants who test positive for Clostridium difficile (C. difficile) at Screening.

- Participants with relapsed/persistent malignancy requiring rapid immune suppression
withdrawal.

- Participants who received an unplanned (not part of the original transplant therapy
plan) donor lymphocyte infusion.

- Participants who received previous systemic treatment for acute GVHD, except for a
maximum of 3 days (72 hours) of 2 mg/kg corticosteroid therapy.

- Participants with unresolved veno-occlusive disease of the liver.

- Participants with creatinine clearance <40 milliliters (mL)/minute at Screening, as
calculated by the Cockcroft-Gault formula.

- Participants known to be infected with human immunodeficiency virus (HIV), hepatitis
B, or hepatitis C.

- Participants known to have an uncontrolled thyroid disorder.

- Participants who are pregnant, breast feeding, or sexually active and unwilling to use
effective birth control for the duration of the study.

- Participants who participated in any other investigational drug trial or had exposure
to any other investigational agent, device, or procedure <4 weeks prior to Screening
and throughout the entire trial, with the exception of investigational drugs
administered prophylactically for cytomegalovirus (CMV) post allogeneic HCT.
We found this trial at
10
sites
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
4100 John R
Detroit, Michigan 48201
800-527-6266
Barbara Ann Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
1364 Clifton Rd NE
Atlanta, Georgia 30322
(404) 712-2000
Emory University Hospital As the largest health care system in Georgia and the only health...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Duarte, California 91010
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Grenoble, Isere 38043
?
mi
from
Grenoble,
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials